Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.39 USD | -1.07% | -3.68% | -10.05% |
05-10 | Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering | MT |
05-08 | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.05% | 1.43B | |
+38.86% | 723B | |
+34.28% | 595B | |
-3.24% | 369B | |
+20.82% | 332B | |
+2.94% | 282B | |
+17.25% | 244B | |
+9.24% | 208B | |
-4.79% | 205B | |
-0.03% | 168B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- BMO Capital Adjusts Price Target on Pacira BioSciences to $60 From $66, Maintains Market Perform Rating